Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31711454 | 0.98 | L3MBTL1 (0.44) | L3MBTL1KMT2AKDM4EGLAGAA | |
| Hydrochloric Acid SCHEMBL999877 | 0.98 | L3MBTL1 (0.44) | L3MBTL1KMT2AKDM4EGLAGAA | |
| SCHEMBL4073047 | 0.88 | KMT2A (0.41) | L3MBTL1KMT2AKDM4EGAAPKM | |
| SCHEMBL17582303 | 0.88 | KDM4E (0.41) | L3MBTL1KMT2AKDM4EGLAGAA | |
| SCHEMBL323522 | 0.86 | KDM4E (0.50) | L3MBTL1KMT2AKDM4EPKMALDH1A1 | |
| SCHEMBL894516 | 0.86 | KDM4E (0.50) | L3MBTL1KMT2AKDM4EPKMALDH1A1 | |
| SCHEMBL3107942 | 0.86 | GNAI3 (0.41) | L3MBTL1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25420232 | 0.84 | GNAO1 (0.43) | KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25420992 | 0.84 | GNAO1 (0.43) | KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL25253971 | 0.84 | GNAO1 (0.43) | KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4402124-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | Prosetta Biosciences, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023069770-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3355699-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | OncoTherapy Science, Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2010094977-A1 | NOVEL BIPHENYL COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009034390-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-7425638-B2 | Cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20040259884-A1 | Cis-imidazolines | HALEY GREGORY JAY (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259884-A1 | Cis-imidazolines | TP53, MDM2, TP53BP1 | L3MBTL1 579/4885KMT2A 4125/4885KDM4E 3892/4885 |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | L3MBTL1 1852/4885KMT2A 4641/4885KDM4E 1485/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | L3MBTL1 2268/4885KMT2A 4124/4885KDM4E 4577/4885 |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | L3MBTL1 2346/4885KMT2A 4108/4885KDM4E 4045/4885 |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | MAVS, SARS1, ZC3HAV1 | L3MBTL1 2381/4885KMT2A 3926/4885KDM4E 3722/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 1850/4885KMT2A 964/4885KDM4E 529/4885 |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | L3MBTL1 383/4885KMT2A 1713/4885KDM4E 3604/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | L3MBTL1 2346/4885KMT2A 4108/4885KDM4E 4045/4885 |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | MAVS, SARS1, ZC3HAV1 | L3MBTL1 2346/4885KMT2A 4108/4885KDM4E 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.